Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
J Am Heart Assoc. 2018 Jan 9;7(1):e007680. doi: 10.1161/JAHA.117.007680.
Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatment-preference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI], -5.4 to 3.0; =0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; =0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; <0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; <0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; =0.76).
Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
尽管有两项大型随机临床试验表明,在 ST 段抬高型心肌梗死患者的直接经皮冠状动脉介入治疗中常规血栓抽吸并无益处,但仍有大量患者接受血栓抽吸。本观察性研究旨在使用瑞典冠状动脉血管造影和血管成形术登记处(SCAAR)的所有可用数据评估血栓抽吸对死亡率、支架血栓形成和卒中的影响。
我们从 2005 年 1 月至 2014 年 9 月期间登记在 SCAAR 的连续 42829 例接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中确定了 42829 例患者。25%的手术中使用了血栓抽吸。我们使用行政医疗区域作为治疗偏好的工具变量进行了工具变量分析,以评估血栓抽吸对死亡率、支架血栓形成和卒中的影响。血栓抽吸与 30 天死亡率(风险降低:-1.2;95%置信区间[CI]:-5.4 至 3.0;=0.57)和 1 年死亡率(风险降低:-2.4;95%CI:-7.6 至 3.0;=0.37)无关。血栓抽吸与 30 天(风险降低:-2.7;95%CI:-4.1 至 -1.4;<0.001)和 1 年(风险降低:-3.5;95%CI:-5.3 至 -1.7;<0.001)的支架血栓形成风险降低相关。住院期间卒中与神经并发症在两组之间无差异(风险降低:0.1;95%CI:-0.8 至 1.1;=0.76)。
两组间死亡率无差异。血栓抽吸与支架血栓形成风险降低相关。我们的研究为先前关于死亡率的随机研究的外部有效性提供了重要证据。